CHEK2 and breast carcinoma: The baseline frequency of all 4,436 CHEK2 VUS carriers was significantly higher in patients over controls [3.4% vs. 2.3%; OR, 1.52; 95% confidence interval (CI), 1.43–1.61] setting a low but significant background breast cancer risk.